Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 19 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Which TKI? An embarrassment of riches for chronic myeloid leukemia patientsHughes, T.; White, D.
2013Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phaseHochhaus, A.; Saglio, G.; Larson, R.; Kim, D.; Etienne, G.; Rosti, G.; De Souza, C.; Kurokawa, M.; Kalaycio, M.; Hoenekopp, A.; Fan, X.; Shou, Y.; Kantarjian, H.; Hughes, T.
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2013Signalling by the βc family of cytokinesHercus, T.; Dhagat, U.; Kan, W.; Broughton, S.; Nero, T.; Perugini, M.; Sandow, J.; D'Andrea, R.; Ekert, P.; Hughes, T.; Parker, M.; Lopez, A.
2013STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent mannerSchafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; White, D.; Hughes, T.; Leclercq, T.
2013Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cellsHiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
2013BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistanceParker, W.; Yeoman, A.; Jamison, B.; Yeung, D.; Scott, H.; Hughes, T.; Branford, S.
2013NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisisWatkins, D.; Hughes, T.; White, D.; D'Andrea, R.
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.